MicroRNAs in rhabdomyosarcoma: Pathogenetic implications and translational potentiality
Genre
ReviewJournal
Date
2011-09-24Author
Rota, RCiarapica, R
Giordano, A
Miele, L
Locatelli, F
Subject
AnimalsBase Sequence
Cell Differentiation
Gene Expression Regulation, Neoplastic
Humans
MicroRNAs
Muscle Development
Muscle, Skeletal
Polycomb-Group Proteins
Repressor Proteins
Rhabdomyosarcoma
Permanent link to this record
http://hdl.handle.net/20.500.12613/5500
Metadata
Show full item recordDOI
10.1186/1476-4598-10-120Abstract
There is growing evidence that interconnections among molecular pathways governing tissue differentiation are nodal points for malignant transformation. In this scenario, microRNAs appear as crucial players. This class of non-coding small regulatory RNA molecules controls developmental programs by modulating gene expression through post-transcriptional silencing of target mRNAs. During myogenesis, muscle-specific and ubiquitously-expressed microRNAs tightly control muscle tissue differentiation. In recent years, microRNAs have emerged as prominent players in cancer as well. Rhabdomyosarcoma is a pediatric skeletal muscle-derived soft-tissue sarcoma that originates from myogenic precursors arrested at different stages of differentiation and that continue to proliferate indefinitely. MicroRNAs involved in muscle cell fate determination appear down-regulated in rhabdomyosarcoma primary tumors and cell lines compared to their normal counterparts. More importantly, they behave as tumor suppressors in this malignancy, as their re-expression is sufficient to restore the differentiation capability of tumor cells and to prevent tumor growth in vivo. In addition, up-regulation of pro-oncogenic microRNAs has also been recently detected in rhabdomyosarcoma.In this review, we provide an overview of current knowledge on microRNAs de-regulation in rhabdomyosarcoma. Additionally, we examine the potential of microRNAs as prognostic and diagnostic markers in this soft-tissue sarcoma, and discuss possible therapeutic applications and challenges of a "microRNA therapy". © 2011 Rota et al; licensee BioMed Central Ltd.Citation to related work
Springer Science and Business Media LLCHas part
Molecular CancerADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.eduae974a485f413a2113503eed53cd6c53
http://dx.doi.org/10.34944/dspace/5482